Compare Autozone Inc (AZO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs Zimmer Biomet Holdings Inc — how do they compare? Autozone Inc trades at $3,034.21 (market cap $49.67B), while Zimmer Biomet Holdings Inc trades at $95.74 (market cap $18.55B). The key difference: Autozone Inc is far larger — about 2.7× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Autozone Inc pays none. Which is the better fit depends on your goals.
| AZO | ZBH | |
|---|---|---|
Market Cap | $49.67B | $18.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $107.71 |
52-Week Low | $2.92K | $79.58 |
Enterprise Value | $62.05B | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,050.43, down 0.57% on the day, with a neutral technical signal and bullish moving averages. The company reported Q1 2026 EPS of $38.07, beating expectations, but revenue growth has slowed with a net income margin of 12.4% in 2025. Analyst consensus is strongly bullish with a $3,730 price target, though recent insider selling and institutional trimming pose sentiment headwinds.
The outlook remains positive given earnings beats and international expansion, but risks include competitive pressures, margin compression, and macroeconomic sensitivity. Upside is supported by a high GF Score of 84 and DCF valuation above $3,800, yet investors should monitor execution on Q2 2026 earnings and capex efficiency.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
